Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Taselisib with fulvestrant slows growth of advanced breast cancer

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 550

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Baselga presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a phase III trial of taselisib, a PI3K targeted therapy, used in combination with hormone therapy fulvestrant.

He describes how the combination halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone, and decreased the chance of cancer worsening by 30%.

For more on these results, read our news coverage here.

Slides from this presentation are available here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation